申请人:Taisho Pharmaceutical Co., Ltd.
公开号:US08022091B2
公开(公告)日:2011-09-20
An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P1), and is useful as a pharmaceutical compound. A compound or a pharmaceutically acceptable salt thereof, which compound is represented by the formula below
(where A represents an oxygen atom, a sulfur atom, a group represented by Formula —SO—, a group represented by Formula —SO2—, or the like, R1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms, or the like, R1A represents a hydrogen atom or the like, R2 represents an alkyl group having 1-6 carbon atoms, a cycloalkyl group having 3-6 carbon atoms, or the like, R3 represents an aryl group, R4 represents a hydrogen atom or an alkyl group having 1-6 carbon atoms and optionally substituted with a carboxyl group, and R5 represents an alkyl group having 1-10 carbon atoms, a cycloalkyl group having 3-8 carbon atoms, an aryl group which is optionally substituted, or the like).
本发明的目的是提供一种具有抑制S1P与其受体Edg-1(S1P1)结合作用的化合物,并且作为药物化合物有用。该化合物或其药学上可接受的盐,该化合物由以下式子表示(其中A代表氧原子,硫原子,由式—SO—表示的基团,由式—SO2—表示的基团或类似的基团,R1代表氢原子,具有1-6个碳原子的烷基或类似的基团,R1A代表氢原子或类似的基团,R2代表具有1-6个碳原子的烷基,具有3-6个碳原子的环烷基或类似的基团,R3代表芳基,R4代表氢原子或具有1-6个碳原子的烷基,可选地被羧基取代,R5代表具有1-10个碳原子的烷基,具有3-8个碳原子的环烷基,可选地被取代的芳基或类似的基团)。